S. Leyman

607 total citations
17 papers, 495 citations indexed

About

S. Leyman is a scholar working on Pharmacology, Psychiatry and Mental health and Experimental and Cognitive Psychology. According to data from OpenAlex, S. Leyman has authored 17 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 6 papers in Psychiatry and Mental health and 5 papers in Experimental and Cognitive Psychology. Recurrent topics in S. Leyman's work include Treatment of Major Depression (6 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (4 papers) and Electroconvulsive Therapy Studies (4 papers). S. Leyman is often cited by papers focused on Treatment of Major Depression (6 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (4 papers) and Electroconvulsive Therapy Studies (4 papers). S. Leyman collaborates with scholars based in Belgium, Croatia and Hungary. S. Leyman's co-authors include A. Mignon, Benjamin Fischler, Marc Ansseau, Adelin Albert, C. Mertens, Myriam Kerkhofs, Luc Staner, Pierre Fossion, Erwin Van Kerschaver and Paul Linkowski and has published in prestigious journals such as Neuropsychopharmacology, SLEEP and Vaccine.

In The Last Decade

S. Leyman

17 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Leyman Belgium 9 214 182 130 103 76 17 495
A. Mignon Belgium 10 119 0.6× 94 0.5× 69 0.5× 96 0.9× 20 0.3× 22 453
Delphine Saragoussi France 13 181 0.8× 262 1.4× 161 1.2× 96 0.9× 75 1.0× 34 630
Rodrigo Muñoz United States 15 68 0.3× 99 0.5× 258 2.0× 137 1.3× 51 0.7× 40 570
Katherine Clarke United Kingdom 7 152 0.7× 104 0.6× 75 0.6× 166 1.6× 42 0.6× 19 473
L. Kola Oyewumi Canada 13 84 0.4× 60 0.3× 454 3.5× 192 1.9× 70 0.9× 34 655
Jeffrey P. Kahn United States 14 193 0.9× 47 0.3× 164 1.3× 172 1.7× 42 0.6× 36 661
Nicholas Myles Australia 14 68 0.3× 109 0.6× 404 3.1× 231 2.2× 54 0.7× 17 738
Sílvia Franco United States 12 81 0.4× 58 0.3× 79 0.6× 258 2.5× 30 0.4× 18 491
Gloria García–Fernández Spain 12 63 0.3× 70 0.4× 85 0.7× 142 1.4× 58 0.8× 48 482
Philip Snaith United Kingdom 7 114 0.5× 52 0.3× 78 0.6× 114 1.1× 48 0.6× 14 367

Countries citing papers authored by S. Leyman

Since Specialization
Citations

This map shows the geographic impact of S. Leyman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Leyman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Leyman more than expected).

Fields of papers citing papers by S. Leyman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Leyman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Leyman. The network helps show where S. Leyman may publish in the future.

Co-authorship network of co-authors of S. Leyman

This figure shows the co-authorship network connecting the top 25 collaborators of S. Leyman. A scholar is included among the top collaborators of S. Leyman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Leyman. S. Leyman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Vrdoljak, Eduard, Lajos Géczi, Jozef Mardiak, et al.. (2015). Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial. Pathology & Oncology Research. 21(3). 775–782. 8 indexed citations
2.
Vrdoljak, Eduard, Martin Gore, S. Leyman, et al.. (2015). Bisphosphonates in Patients with Renal Cell Carcinoma and Bone Metastases: A Sunitinib Global Expanded-Access Trial Subanalysis. Future Oncology. 11(20). 2831–2840. 8 indexed citations
3.
Vrdoljak, Eduard, et al.. (2014). Use of bisphosphonates in combination with sunitinib in renal cell cancer patients with bone metastases from the Expanded Access Study. 1 indexed citations
4.
Vrdoljak, Eduard, László Torday, Avishay Sella, et al.. (2013). Insights into cancer surveillance in C entral and E astern E urope, I srael and T urkey. European Journal of Cancer Care. 24(1). 99–110. 7 indexed citations
5.
Ansseau, Marc, et al.. (2009). Objective: remission of depression in primary care. European Neuropsychopharmacology. 19(3). 169–176. 22 indexed citations
6.
7.
Smets, F., Annick Bourgois, C. Vermylen, et al.. (2007). Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine. 25(29). 5278–5282. 26 indexed citations
8.
Ansseau, Marc, et al.. (2005). Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. European Psychiatry. 20(3). 229–235. 64 indexed citations
9.
Malfroot, Anne, et al.. (2004). A cross-sectional survey of the prevalence of Streptococcus pneumoniae nasopharyngeal carriage in Belgian infants attending day care centres. Clinical Microbiology and Infection. 10(9). 797–803. 30 indexed citations
10.
Nayer, André, Michel Schittecatte, Jean-Luc Evrard, et al.. (2002). Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. The International Journal of Neuropsychopharmacology. 5(2). 115–20. 63 indexed citations
11.
Zdanowicz, Nicolas, et al.. (2002). Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 8(2). 63–68. 6 indexed citations
12.
Nayer, André, M. Ansseau, Hugo D’Haenen, et al.. (2002). An eight-week, open-label, uncontrolled, multicenter, Phase IV study of remission rates in outpatients and inpatients with major depression treated with venlafaxine. Current Therapeutic Research. 63(8). 475–485. 3 indexed citations
13.
Dufour, André, et al.. (2001). Clinical acceptability of venlafaxine extended release and paroxetine in outpatients treated for depression by general practitioners. European Neuropsychopharmacology. 11. S224–S225. 3 indexed citations
14.
Leyman, S., et al.. (1995). Efficacy and tolerance of once-daily quinapril in mild to moderate arterial hypertension. Efficacy evaluated by a 24-hour monitoring of arterial blood pressure. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 21. 205–215. 1 indexed citations
15.
16.
Reynaert, Christine, et al.. (1994). A double-blind study of paroxetine and maprotiline in major depression. Neuropsychopharmacology. 11(4). 274–274. 1 indexed citations
17.
Mertens, C., et al.. (1993). A double‐blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatrica Scandinavica. 87(2). 141–145. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Mignon Breakdown of academic impact, for papers by Delphine Saragoussi Breakdown of academic impact, for papers by Rodrigo Muñoz Breakdown of academic impact, for papers by Katherine Clarke Breakdown of academic impact, for papers by L. Kola Oyewumi Breakdown of academic impact, for papers by Jeffrey P. Kahn Breakdown of academic impact, for papers by Nicholas Myles Breakdown of academic impact, for papers by Sílvia Franco Breakdown of academic impact, for papers by Gloria García–Fernández Breakdown of academic impact, for papers by Philip Snaith
Rankless by CCL
2026